237.26
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$237.43
Offen:
$236.37
24-Stunden-Volumen:
215.95K
Relative Volume:
0.27
Marktkapitalisierung:
$34.88B
Einnahmen:
$4.93B
Nettoeinkommen (Verlust:
$1.25B
KGV:
28.01
EPS:
8.47
Netto-Cashflow:
$1.38B
1W Leistung:
-2.16%
1M Leistung:
+1.51%
6M Leistung:
+10.57%
1J Leistung:
+30.04%
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RMD
Resmed Inc
|
237.37 | 34.88B | 4.93B | 1.25B | 1.38B | 8.47 |
![]()
ISRG
Intuitive Surgical Inc
|
590.72 | 211.02B | 8.35B | 2.32B | 1.30B | 6.41 |
![]()
BDX
Becton Dickinson Co
|
227.87 | 65.90B | 20.64B | 1.73B | 2.94B | 6.02 |
![]()
ALC
Alcon Inc
|
88.65 | 44.42B | 9.76B | 1.16B | 665.00M | 2.34 |
![]()
WST
West Pharmaceutical Services Inc
|
318.69 | 23.39B | 2.88B | 499.60M | 321.60M | 6.74 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-01-16 | Eingeleitet | Goldman | Buy |
2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
2024-12-13 | Eingeleitet | Stifel | Hold |
2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
2024-09-04 | Herabstufung | Needham | Buy → Hold |
2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2023-09-06 | Hochstufung | Needham | Hold → Buy |
2023-09-05 | Herabstufung | UBS | Buy → Neutral |
2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2023-05-23 | Eingeleitet | UBS | Buy |
2023-04-14 | Eingeleitet | Mizuho | Buy |
2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
2022-10-12 | Eingeleitet | Jefferies | Hold |
2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
2021-08-02 | Herabstufung | Needham | Buy → Hold |
2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
2021-06-21 | Bestätigt | Needham | Buy |
2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
2021-03-16 | Hochstufung | Needham | Hold → Buy |
2020-11-02 | Hochstufung | UBS | Neutral → Buy |
2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-02-03 | Eingeleitet | CLSA | Underperform |
2020-01-31 | Herabstufung | UBS | Buy → Neutral |
2020-01-10 | Eingeleitet | Oppenheimer | Perform |
2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
2019-07-29 | Hochstufung | UBS | Neutral → Buy |
2019-07-16 | Herabstufung | UBS | Buy → Neutral |
2019-05-06 | Hochstufung | UBS | Neutral → Buy |
2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Kestra Private Wealth Services LLC Increases Stock Position in ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed CFO Executes Planned Stock Transaction - TipRanks
ResMed Getting Closer To Key Technical Benchmark - MSN
ResMed Close To Joining Very Elite Stock Group - Investor's Business Daily
Stephens Inc. AR Decreases Stock Position in ResMed Inc. (NYSE:RMD) - MarketBeat
Ex-Dividend Reminder: TJX Companies, UNITIL and ResMed - Nasdaq
Down 4%, is the ResMed share price in the buy zone? - MSN
Research Analysts Issue Forecasts for ResMed Q3 Earnings - MarketBeat
Resmed Chief Financial Officer Sells 1,000 Shares -February 10, 2025 at 06:33 pm EST - Marketscreener.com
Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions - Seeking Alpha
Why ResMed (RMD) is a Top Growth Stock for the Long-Term - Yahoo Finance Australia
Insider Selling: ResMed Inc. (NYSE:RMD) Director Sells 2,000 Shares of Stock - MarketBeat
Sumitomo Mitsui Trust Group Inc. Trims Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. (NYSE:RMD) Stock Position Lifted by Mirae Asset Global Investments Co. Ltd. - MarketBeat
ResMed Inc Announces Proposed Sale of Securities by Officer - TipRanks
Tobam Lowers Stock Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
With 69% ownership, ResMed Inc. (NYSE:RMD) boasts of strong institutional backing - Yahoo Finance
Stephens Investment Management Group LLC Decreases Position in ResMed Inc. (NYSE:RMD) - MarketBeat
State of Alaska Department of Revenue Lowers Position in ResMed Inc. (NYSE:RMD) - MarketBeat
Capital Investment Services of America Inc. Sells 1,961 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
What is William Blair's Estimate for ResMed FY2025 Earnings? - MarketBeat
1,438 Shares in ResMed Inc. (NYSE:RMD) Acquired by Chicago Partners Investment Group LLC - MarketBeat
Jericho Financial LLP Makes New Investment in ResMed Inc. (NYSE:RMD) - MarketBeat
abrdn plc Lowers Stock Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
William Blair Weighs in on ResMed’s Q3 Earnings (NYSE:RMD) - Defense World
ResMed (NYSE:RMD) Shares Gap Up on Analyst Upgrade - MarketBeat
ResMed Inc. (NYSE:RMD) Stock Holdings Increased by Spire Wealth Management - MarketBeat
ResMed Inc. (NYSE:RMD) Stock Position Lowered by Oak Family Advisors LLC - MarketBeat
Chicago Capital LLC Purchases 3,551 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc Director Plans Sale of 2,000 Shares - MSN
Cibc World Market Inc. Grows Stake in ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. Reports Changes in CDI and Security Issuances - MSN
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus.com
Looking to bag the record high ResMed dividend? You better hurry! - MSN
ResMed Inc. Announces Changes in Beneficial Ownership - TipRanks
ResMed (NYSE:RMD) Given New $280.00 Price Target at KeyCorp - MarketBeat
ResMed (NYSE:RMD) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes" - MSN
ResMed: Digital Health Drives Q2 Growth - MSN
BDF Gestion Sells 1,532 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
Resmed Incorporated's Fiscal 2Q Revenue, NPAT Results Above Consensus; Jarden Research Says - Marketscreener.com
Zacks Research Issues Optimistic Outlook for ResMed Earnings - MarketBeat
ResMed Inc. (NYSE:RMD) Declares $0.53 Quarterly Dividend - MarketBeat
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):